Atopic Dermatitis

A recap of the 7 phase 3 trials presented during the 2025 AAD annual meeting's late-breaking sessions.

This interview highlights recent findings on roflumilast cream 0.05% for patients aged 2 to 5 years with mild to moderate atopic dermatitis.

New data presented at AAD 2025 point to impacts on multiple disease nodes as needed to achieve high levels of efficacy.

These data, presented at AAD 2025, highlight the efficacy of upadacitinib in clearing skin among patients with atopic dermatitis compared to those given dupilumab.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress.

A group of 9 experts reflect on what they are looking forward to most in 2025 following the AAD annual meeting.

This interview with Andrew Alexis, MD, MPH, features some of the most notable highlights from his AAD 2025 talks on therapeutic and diagnostic pearls for skin of color.

Panelists discuss how common adverse effects impact treatment decisions, requiring adjustments. Experienced adverse reactions are managed with tailored interventions, monitoring, and patient education to ensure optimal care.

Panelists discuss how primary care awareness of biologics and Janus kinase (JAK) inhibitors for atopic dermatitis (AD) remain limited, with outreach efforts by dermatology groups and industry partners showing mixed success in education. While patients on biologics generally report significant symptom improvement, measured through validated tools like EASI, SCORAD, and patient-reported outcome measures, ongoing efforts are needed to bridge the knowledge gap in primary care settings.

An analysis of data from the DELTA program at AAD 2025 sheds light on the efficacy of delgocitinib for chronic hand eczema.

Data at AAD 2025 and an announcement from Amgen provide insight into the potential role of rocatinlimab in atopic dermatitis.

Stein Gold highlights her team's findings on tapinarof cream (Vtama) 1% from the 48-week ADORING 3 extension for those aged 2 to 17 with atopic dermatitis.

David Rosmarin, MD, discusses results from ADORING 3 presented at AAD 2025.

New 3-year data from ADjoin demonstrate the efficacy and safety profile of lebrikizumab in moderate to severe atopic dermatitis.

Eapen discussed her research into analyzing the cord blood methylome for markers that predict atopic dermatitis risk at the AAAAI/WAO Joint Congress.

Greiwe discussed findings from the phase 3 ADORING 1 and 2 trials in people as young as 2 years of age.

In these survey findings, a variety of notable findings regarding perceptions of awareness of CHE as well as views on available drugs are highlighted.

A preview of 5 phase 3 clinical trials being presented during the AAD 2025 annual meeting's late-breaking sessions.

Panelists discuss how the emergence of targeted biologics has revolutionized atopic dermatitis treatment by offering effective alternatives to traditional therapies. These agents, including IL-4/IL-13 inhibitors like dupilumab and others targeting specific inflammatory pathways, have provided new options for moderate to severe cases resistant to conventional treatments.

Panelists discuss the current treatment landscape for atopic dermatitis, noting significant advances in biologics and systemic therapies, and share optimism about the future of management, highlighting ongoing research and the potential for more targeted, personalized treatments to improve patient outcomes.

Panelists discuss how upcoming topical therapeutics for atopic dermatitis include corticosteroid-sparing treatments like topical calcineurin inhibitors (eg, tacrolimus, pimecrolimus), Janus kinase (JAK) inhibitors (eg, ruxolitinib), and phosphodiesterase-4 inhibitors (eg, crisaborole) for effective symptom management.

Our top 5 headlines include an FDA approval, a pair of submissions, data from AAAAI 2025, and more!

Alexis discussed the latest research in the field and new management strategies for children with atopic dermatitis.

These phase 3 data on delgocitinib cream (Anzupgo) 20 mg/g highlight the drug’s potential for adolescents aged 12 years and older with chronic hand eczema (CHE).

Chovatiya discussed his talk at the 2025 AAAAI/WAO Joint Congress.